olivLaw · US equity research
Evogene Ltd. EVGN
Agricultural Chemicals · SIC 2870 · Vertical: Agricultural Chemicals (SIC 2870)
Evogene Ltd. is a biotechnology company that uses its computational platform, ChemPass AI and GeneRator AI, to discover products for agriculture, human health and industrial applications. In 2025 the company sharply reduced its activity and sold part of its subsidiaries' assets, with the operating loss falling to about 14.0 million USD, placing it in a restructuring phase focused on a few platforms.
The AI analysis may be outdated: new filings came after its sources (see the «AI analysis» section).
At the close of 04 Nov 2026, Evogene Ltd. (EVGN) stock was 0.36 USD (−0.89% on the day), with market capitalisation 3.1 m USD, P/E 0.3 on diluted EPS of 1.08 USD over the last 12 months, beta 0.83, 52-week range 0.36–1.25 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 38.8
- weak (30–45)
- Bollinger (20, 2)
- 0.35 – 0.40
- in the lower half of the band · %B 0.14 · band width 13.9%
- SMA 50 / 200
- 0.44 / 0.67
- downtrend (price < SMA50 < SMA200)
- MACD (12, 26, 9)
- -0.02 / -0.02
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −10.8% | −1.1% | −9.7 pp | — |
| 3 months | −43.4% | −0.5% | −42.9 pp | — |
| 6 months | −54.8% | +4.4% | −59.2 pp | — |
| Year to date | −67.6% | +12.3% | −79.9 pp | — |
| 1 year | −70.8% | +13.5% | −84.3 pp | −10.3% |
| 3 years | −93.8% | +76.4% | −170.3 pp | −24.4% |
| 5 years | −98.7% | +63.7% | −162.4 pp | — |
Price returns, dividends excluded.
Quarterly results
ESEF annual reports carry no quarters: the results are annual (below).
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Today's P/E sits at the 0 percentile of its own 1-quarter history (min 1.0, median 1.0, max 1.0; quarters with earnings only).
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | ⚠ 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.7 m | 753.0 k | 1.0 m | 930.0 k | 1.7 m | 3.0 m | 5.6 m | 3.9 m |
| Revenue YoY | −48.3% | −56.9% | +38.1% | −10.6% | +80.1% | — | +87.0% | −30.9% |
| Net income | -20.8 m | -18.1 m | -23.4 m | -27.8 m | -26.6 m | -23.9 m | -16.5 m | -8.5 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable | unavailable | — | unavailable | unavailable |
| Diluted EPS | unavailable | unavailable | -0.83 | -0.69 | -6.44 | -5.20 | -2.90 | 1.08 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | unavailable | — | unavailable | unavailable |
| net % | -1,188.2% | -2,405.3% | -2,247.5% | -2,988.5% | -1,590.3% | -800.8% | -295.6% | -220.2% |
| Free cash flow | -15.5 m | -18.6 m | -20.2 m | -25.6 m | -24.8 m | -22.2 m | -20.3 m | -13.6 m |
The series breaks before 2023: earlier years come from the original reports of the issuer of that time, later years from a subsequent filing that restated the perimeter (a separation, discontinued operations). The year-on-year change across the break is not shown.
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 13.0 m USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- 12.0 m USD
- Total assets
- 20.0 m USD
- Debt / equity
- unavailable
- Current ratio
- 4.54x
- ROE
- -63.3%
- ROA
- -28.3%
- FCF margin
- -353.9%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 1.0 m | 930.0 k | 1.7 m | 3.0 m | 5.6 m | 3.9 m | SEC (XBRL)· 26 Mar 2026verified |
| Cost of revenue | 574.0 k | 767.0 k | 909.0 k | 1.5 m | 2.4 m | 4.1 m | SEC (XBRL)· 26 Mar 2026verified |
| Gross profit | 466.0 k | 163.0 k | 766.0 k | 1.5 m | 3.2 m | -241.0 k | SEC (XBRL)· 26 Mar 2026verified |
| Research & development | 17.3 m | 21.1 m | 20.8 m | 16.2 m | 12.5 m | 8.0 m | SEC (XBRL)· 26 Mar 2026verified |
| Operating income | -24.8 m | -31.0 m | -26.9 m | -22.2 m | -18.8 m | -14.0 m | SEC (XBRL)· 26 Mar 2026verified |
| Interest expense | 3.0 m | 1.4 m | 3.3 m | 928.0 k | 3.4 m | 1.9 m | SEC (XBRL)· 26 Mar 2026verified |
| Pre-tax income | -26.2 m | -30.4 m | -29.8 m | -21.9 m | -14.8 m | -13.5 m | SEC (XBRL)· 26 Mar 2026verified |
| Income tax | 32.0 k | 13.0 k | 90.0 k | 19.0 k | 9.0 k | 1.0 k | SEC (XBRL)· 26 Mar 2026verified |
| Net income | -23.4 m | -27.8 m | -26.6 m | -23.9 m | -16.5 m | -8.5 m | SEC (XBRL)· 26 Mar 2026verified |
| Diluted EPS | -0.83 | -0.69 | -6.44 | -5.20 | -2.90 | 1.08 | SEC (XBRL)· 26 Mar 2026verified |
| Weighted average diluted shares | 28.2 m | 40.4 m | 4.1 m | 4.6 m | 5.7 m | 7.9 m | SEC (XBRL)· 26 Mar 2026verified |
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 46.2 m | 32.3 m | 29.0 m | 20.8 m | 15.3 m | 13.0 m | SEC (XBRL)· 26 Mar 2026verified |
| Inventories | 0 | 92.0 k | 566.0 k | 76.0 k | 1.8 m | 210.0 k | SEC (XBRL)· 26 Mar 2026verified |
| Current assets | 51.8 m | 56.9 m | 37.8 m | 34.5 m | 21.6 m | 15.6 m | SEC (XBRL)· 26 Mar 2026verified |
| Property, plant & equipment, net | 2.1 m | 2.1 m | 2.5 m | 2.5 m | 1.8 m | 812.0 k | SEC (XBRL)· 26 Mar 2026verified |
| Intangibles (excl. goodwill) | 16.1 m | 15.2 m | 14.1 m | 13.2 m | 12.2 m | 0 | SEC (XBRL)· 26 Mar 2026verified |
| Total assets | 71.9 m | 76.3 m | 56.1 m | 51.1 m | 39.9 m | 20.0 m | SEC (XBRL)· 26 Mar 2026verified |
| Accounts payable | 863.0 k | 1.5 m | 1.0 m | 1.8 m | 1.2 m | 639.0 k | SEC (XBRL)· 26 Mar 2026verified |
| Current liabilities | 9.7 m | 6.9 m | 5.6 m | 6.9 m | 18.7 m | 3.4 m | SEC (XBRL)· 26 Mar 2026verified |
| Total liabilities | — | — | — | 22.4 m | 25.0 m | 8.1 m | SEC (XBRL)· 26 Mar 2026verified |
| Equity | 56.9 m | 63.4 m | 34.8 m | 28.7 m | 14.8 m | 12.0 m | SEC (XBRL)· 26 Mar 2026verified |
| Shares outstanding at year end | 35.6 m | 41.2 m | 41.3 m | 50.6 m | 6.5 m | 8.7 m | SEC (XBRL)· 26 Mar 2026verified |
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -19.5 m | -24.7 m | -23.7 m | -21.6 m | -19.7 m | -13.5 m | SEC (XBRL)· 26 Mar 2026verified |
| Capex | 682.0 k | 847.0 k | 1.2 m | 577.0 k | 626.0 k | 135.0 k | SEC (XBRL)· 26 Mar 2026verified |
| Free cash flow | -20.2 m ≈ | -25.6 m ≈ | -24.8 m ≈ | -22.2 m ≈ | -20.3 m ≈ | -13.6 m ≈ | SEC (XBRL)· 26 Mar 2026derived |
| Investing cash flow | 9.4 m | -20.6 m | 13.3 m | -4.5 m | 9.6 m | 17.7 m | SEC (XBRL)· 26 Mar 2026verified |
| Financing cash flow | 20.4 m | 30.3 m | 9.3 m | 18.2 m | 4.7 m | -6.6 m | SEC (XBRL)· 26 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
Risk
Valuation
olivLaw classification
- score weight coverage: 43.8% of at least 60%
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 3.1 m USD
Key indicators
Coverage and freshness
Score by group
44% · Insufficient data
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 11.16 – 19.40 USD.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (USD per share)
— — Mid · ▏ Price
Valuation methods
- DCF (discounted cash flow)unavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/E11.16 – 19.40 (Mid 14.37)4 companies used · median multiple 13.3x · quartiles 10.3x – 18.0xCF, ICL, NTR, UAN
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: score weight coverage: 43.8% of at least 60%
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | -220.2% | 20 (vs peers) | 14% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | 32.0% | 100 (on a fixed band) | 19% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | -7.3x | 0 (on a fixed band) | 14% |
| Current ratio · Balance sheet | 4.5x | 100 (on a fixed band) | 10% |
| P/E (TTM) · Valuation | 0.3x | 100 (vs peers) | 24% |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -438.4% | 0 (on a fixed band) | 19% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet40/100 · 2/3 factors with a value
- Growth· partial100/100 · 1/2 factors with a value
- Quality· partial20/100 · 1/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation56/100 · 2/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
EVOGENE LTD. (EVGN). Latest full fiscal year: 2025; data up to 2025-12-31.
Figures computed from the financial statements: revenue 3.9 m USD in 2025; YoY growth -30.9%; net margin -220.2%.
The estimated value range is 11.16–19.40 USD per share (median of 1 methods, agreement: single method); assumptions are illustrative. Against the central value of 14.37 USD, the price of 0.36 USD leaves a potential of 3,926.1% (value / price − 1) and a margin of safety of 97.5% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
Insufficient data for a verdict (score weight coverage: 43.8% of at least 60%).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Revenue CAGR 3Y: 32.0%
- Current ratio: 4.5x
- P/E (TTM): 0.3x
- The price is below the estimated value range
What contradicts it
- Net margin: -220.2%
- Interest coverage: -7.3x
- FCF yield: -438.4%
Not assessed (insufficient data or a ratio without meaning): ROIC, FCF conversion, EPS CAGR 3Y, Net debt / EBITDA, EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Agricultural Chemicals (SIC 2870) · same industry (4-digit SIC) · compared with 10 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| NTRNutrien Ltd. | 41.0 bn | 15.5 | 9.1% | 8.4% | +3.5% | +24% / +35% |
| CFCf Industries Holdings, Inc. | 16.9 bn | 7.9 | 46.7% | 32.3% | +19.3% | +42% / +49% |
| MOSMosaic Co | 6.9 bn | — | -9.3% | -9.4% | +8.4% | −12% / −40% |
| ICLIcl Group Ltd. | 5.9 bn | 25.4 | 3.9% | 3.2% | +4.6% | −18% / −9% |
| SMGScotts Miracle-Gro Co | 3.9 bn | 55.8 | — | 2.1% | −3.9% | +19% / +21% |
| UANCvr Partners, LP | 1.2 bn | 11.1 | — | 16.1% | +15.4% | +16% / +64% |
| AVDAmerican Vanguard Corporation | 28.8 m | — | -26.5% | -10.7% | −5.9% | −79% / −90% |
| BIOXBioceres Crop Solutions Corp. | 16.2 m | — | -19.1% | -16.5% | −27.9% | −85% / −98% |
| SNESSenestech, Inc. | 6.6 m | — | -107.4% | -294.7% | +19.6% | −58% / −87% |
| CBUSCibus, Inc. | 6.2 m | — | -225.9% | -2,258.9% | −14.6% | −9% / −90% |
| EVGNEvogene Ltd. | 3.1 m | 0.3 | — | -220.2% | −30.9% | −71% / −94% |
1- and 3-year price returns: for EVGN from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 26 Mar 2026; since then the company filed 6-K (28 Oct 2026), 6-K (06 Oct 2026), 6-K (30 Sept 2026), 6-K (28 Sept 2026), 6-K (15 Sept 2026), 6-K (04 Sept 2026).
In brief
Evogene Ltd. is a biotechnology company that uses its computational platform, ChemPass AI and GeneRator AI, to discover products for agriculture, human health and industrial applications. In 2025 the company sharply reduced its activity and sold part of its subsidiaries' assets, with the operating loss falling to about 14.0 million USD, placing it in a restructuring phase focused on a few platforms.
SWOT
Strengths
- Its proprietary computational platform and discovery engines ChemPass AI and GeneRator AI offer a technological edge that can be applied across several fields.
- The structure of specialized subsidiaries lets each unit develop its own portfolio and commercial strategy.
- The company has shown it can sell assets and sign licensing agreements that bring in cash at critical moments.
Weaknesses
- The company continues to record operating losses and has not yet reached profitability.
- Conditions exist that raise substantial doubt about its ability to continue as a going concern over a one-year horizon.
- Revenues are small and concentrated among a few customers and regions, and royalty revenues have not yet been generated.
Opportunities
- Collaborations with large agriculture and pharma partners could bring development payments, milestones and sales revenues.
- A focus on AI-powered drug discovery could open new contracts in the pharmaceutical sector.
- Monetizing subsidiary assets through licensing or sales could raise funds without issuing new shares.
Threats
- If funding is not available on acceptable terms, activity could be reduced or stopped.
- Issuing new shares or warrants could dilute existing shareholders and could reduce the share price.
- Falling demand in core markets and delays in clinical or research programs could weigh on results.
Risks
- Continued losses and going concern riskhigh
The company expects to keep incurring losses until it earns significant revenues, and management has identified conditions that raise doubt about its ability to continue as a going concern 1.
- Need for additional capitalhigh
The company and its subsidiaries could need substantial funding, and new sources could bring dilution, restrictive covenants or the relinquishing of product rights 1.
- Increased operational concentrationmedium
After reducing the number of subsidiaries and business lines, failures in a few platforms or projects could have a larger impact than in the past 1.
- Dilution of stakes in subsidiariesmedium
External financing of subsidiaries reduces the company's ownership percentage and can lower revenues and benefits for shareholders 1.
- Scientific outcome uncertaintymedium
Discoveries and candidate products may not achieve the desired effect, and years of research may never translate into commercial products 1.
Investment thesis
What would need to be true (bull case)
- If the ChemPass AI platform wins contracts in the pharma sector, the company could diversify revenues and reduce its dependence on agricultural activity.
- Cost reductions and asset sales could lead to a faster path toward financial balance if these measures are sustained.
- Collaboration agreements with large industrial partners could bring milestone payments and royalties that support the company's value.
What would break the thesis
- Persistent operating losses and doubt about the going concern could force new share issuances with significant dilution.
- Revenue concentration among a few customers and regions makes the company vulnerable to demand shifts, as the castor seed decline showed.
- If discoveries do not reach commercialization, the research investment might not be recovered.
What to watch
- Trend in revenues from the agriculture and industrial segmentsQ1 2027
- New collaboration or licensing agreements, including for ChemPass AI2027
- New funding sources and any share or warrant issuancesnext 10-K
- Results of the BMC128 clinical trial at subsidiary Biomica2026
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 26 Mar 2026; since then the company filed 6-K (28 Oct 2026), 6-K (06 Oct 2026), 6-K (30 Sept 2026), 6-K (28 Sept 2026), 6-K (15 Sept 2026), 6-K (04 Sept 2026).
The business
Evogene operates as a technology hub that licenses its computational discovery engines to specialized subsidiaries, each with its own management and commercial strategy. Revenues come mainly from research and development payments, collaboration agreements and limited sales, and the company has not yet generated royalty revenues. Total revenues in 2025 were 3.853 million USD, down from the prior year, and the operating loss from continuing operations fell to 14.0 million USD from 18.8 million USD in 2024 1.
Segments
Industrial applications
The industrial segment focuses on improved castor bean seeds for industrial uses, including biofuels, through subsidiary Casterra. Segment revenues were 2.168 million USD in 2025 1. Demand for castor seeds declined significantly by the end of 2025, and activity has concentrated on the Brazilian market.
Market context
Evogene operates in industries with long research cycles, where value depends on converting discoveries into marketable products. The geographic mix of revenues shifted sharply: in 2025 Africa accounted for 53 percent of revenues and Europe for 26 percent, compared with 31 and 41 percent in 2024 1. This geographic concentration makes revenues dependent on a few customers and conditions in a few markets.
Trends
- Demand for computational and AI-based productstailwind
The use of artificial intelligence in molecule discovery and computational biology could shorten research time and cost, which could support the value of the ChemPass AI platform. The company intends to focus its efforts on AI-powered drug discovery in the pharma sector 1.
- Decline in demand for castor seedsheadwind
Demand for castor seeds used for biofuels fell significantly by the end of 2025, leading Casterra to cease operations in Kenya and reduce its cost base 1.
- Portfolio consolidation and asset salesmixed
Asset sales and workforce reductions in 2025 may lower costs but can also limit diversification and long-term growth options. The net effect depends on the success of the remaining platforms 1.
- Funding pressure and dilutionheadwind
A lack of sufficient capital could force group companies to accept less favorable terms or relinquish rights to products, which could reduce benefits for shareholders 1.
Competitive position
Evogene competes with other biotechnology and agrochemical companies that use computer-assisted discovery, as well as with large industrial partners developing their own internal platforms. The source does not provide details on the competitive position of each rival, so the comparison is limited to the company's fields of activity.
- CortevaCTVA
Partner with which Lavie Bio had a licensing agreement for bio-fungicides, terminated in November 2024; appears as both competitor and partner in agriculture.
- Bayer
Partner of AgPlenus for developing a weed control solution, with an exclusive license for products developed in the collaboration.
- ICL
Company that acquired most of Lavie Bio's activities and the MicroBoost AI technology for agriculture.
- Lishan Technologies
Party that received the license for BMC128 from Biomica, competing in the microbiome therapeutics area.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- Evogene (EVGN) Q2 2026 Earnings Call TranscriptYahoo Finance — News · 25 Aug 2026 · EN
The latest news item in our archive is from 25 Aug 2026; the newest SEC filing is from 28 Oct 2026. The press archive comes from the RSS feeds we follow and does not necessarily cover the latest event — the filings alongside do.
SEC filings
- Current report (foreign issuer)28 Oct 2026
- Current report (foreign issuer)06 Oct 2026
- Current report (foreign issuer)30 Sept 2026
- Current report (foreign issuer)28 Sept 2026
- Current report (foreign issuer)15 Sept 2026
- Current report (foreign issuer)04 Sept 2026
- Current report (foreign issuer)27 Aug 2026
- Current report (foreign issuer)18 Aug 2026
- Current report (foreign issuer)31 Jul 2026
- Current report (foreign issuer)17 Jul 2026
Sources
- [1] Form 20-F, fiscal year ended 2025-12-31 · SEC / Evogene Ltd. · 26 Mar 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.